Accelerating Biologics
Development with Confidence
Complex trials demand intelligent solutions

In today's biologics development landscape, success demands more than just technology – it requires deep understanding of the unique challenges facing sponsors and CROs. From managing temperature-sensitive, expensive drug supplies to capturing high-quality patient experience data for regulatory submissions and value demonstration, every aspect of biologics trials brings distinct complexities.
That's where Signant Health's comprehensive eClinical solutions and services make the difference.
Why choose Signant Health?
Our leading suite of solutions addresses the core challenges of biologics clinical development:


Minimize investigational product wastage

Our RTSM and GxP Inventory solutions deliver sophisticated planning and management of temperature-sensitive, expensive, short-expiry biologics – minimizing wastage and enabling accurate mid-trial planning, while ensuring optimal supply across all trial sites.

Capture highest-quality data

Our eCOA solutions provide comprehensive capture of patient (PRO), observer (ObsRO) and clinician (ClinRO) reported outcomes data supporting efficacy, safety and immunogenicity endpoints – vital data supporting both regulatory decisions and value demonstrations for price negotiations under the Inflation Reduction Act (IRA).

Simplify participation in complex trials

From rare disease studies to pediatric populations, our decentralized elements – including eConsent and TeleVisits – reduce participation barriers and enhance patient engagement.

Expert guidance

With deep experience across autoimmune disorders, oncology, pediatrics and rare diseases, our scientific and operational teams provide strategic input from protocol development through study completion.

Our RTSM and GxP Inventory solutions deliver sophisticated planning and management of temperature-sensitive, expensive, short-expiry biologics – minimizing wastage and enabling accurate mid-trial planning, while ensuring optimal supply across all trial sites.

Our eCOA solutions provide comprehensive capture of patient (PRO), observer (ObsRO) and clinician (ClinRO) reported outcomes data supporting efficacy, safety and immunogenicity endpoints – vital data supporting both regulatory decisions and value demonstrations for price negotiations under the Inflation Reduction Act (IRA).

From rare disease studies to pediatric populations, our decentralized elements – including eConsent and TeleVisits – reduce participation barriers and enhance patient engagement.

With deep experience across autoimmune disorders, oncology, pediatrics and rare diseases, our scientific and operational teams provide strategic input from protocol development through study completion.
MEETING TIMELINE COMMITMENTS
OUR EXPERIENCE IN BIOLOGICS TRIALS
Ready to boost your biologics trial?
Get the competitive edge you need: Our eCOA solutions not only enhance the efficiency and quality of your trials but also support the robust value demonstration crucial in the post-IRA environment.